Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics

Devendra Pade; Masoud Jamei; David B. Turner; Bipin Mistry; Marilyn N. Martinez

doi:10.1016/j.ejpb.2019.05.024

Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics

Devendra Pade, Masoud Jamei, David B. Turner, Bipin Mistry, Marilyn N. Martinez

In: European Journal of Pharmaceutics and Biopharmaceutics · 2019 · vol. 141 , pp. 191–209 · doi:10.1016/j.ejpb.2019.05.024 · PMID:31150808 · W2947444671

article OA: closed CC0 ⤵ 1 in-corpus citation

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study developed a mechanistic model to describe danazol oral absorption in fasted dogs, demonstrating how formulation characteristics influence drug pharmacokinetics.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (53)

A dynamic in vitro lipolysis model via openalex
Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats via openalex
Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug via openalex
Evaluation of a Nanoemulsion Formulation Strategy for Oral Bioavailability Enhancement of Danazol in Rats and Dogs via openalex
Formulation and Performance of Danazol Nano-crystalline Suspensions and Spray Dried Powders via openalex
Formulation of a Danazol Cocrystal with Controlled Supersaturation Plays an Essential Role in Improving Bioavailability via openalex
<i>In Vivo</i> Precipitation of Poorly Soluble Drugs from Lipid-Based Drug Delivery Systems via openalex
Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis via openalex
Non-linear Increases in Danazol Exposure with Dose in Older vs. Younger Beagle Dogs: The Potential Role of Differences in Bile Salt Concentration, Thermodynamic Activity, and Formulation Digestion via openalex
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex
Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules via openalex
Solubilization and Wetting Effects of Bile Salts on the Dissolution of Steroids via openalex
Surface treatment of the hydrophobic drug danazol to improve drug dissolution via openalex
Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation via openalex
W6635782166 via openalex
W6676438963 via openalex
W6682034404 via openalex
W6685495014 via openalex
W6687251196 via openalex
doi:10.1371/annotation/10ae05dc-90cb-46f1-aa2b-e63eb4a132e2 via openalex
doi:10.1002/jps.20212 via openalex
doi:10.1023/b:modi.0000006562.93049.36 via openalex
doi:10.2133/dmpk.24.53 via openalex
doi:10.1016/s0928-0987(02)00251-8 via openalex
doi:10.1007/978-1-4419-1087-5_10 via openalex
doi:10.1016/j.addr.2016.04.018 via openalex
doi:10.1016/j.jcis.2006.10.008 via openalex
doi:10.1016/j.ejps.2013.02.006 via openalex
doi:10.1007/s11095-008-9637-9 via openalex
doi:10.1016/j.ijpharm.2008.10.001 via openalex
doi:10.1007/s11095-016-1871-y via openalex
doi:10.1002/bdd.2072 via openalex
doi:10.1016/s0090-9556(24)15037-4 via openalex
doi:10.1002/9783906390468 via openalex
doi:10.1517/17425250802691074 via openalex
doi:10.1021/js960075u via openalex
doi:10.1016/j.ijpharm.2017.10.058 via openalex
doi:10.1002/9783906390468.ch16 via openalex
doi:10.1002/jps.22154 via openalex
doi:10.5402/2012/195727 via openalex
doi:10.1016/j.molliq.2016.02.081 via openalex
doi:10.3109/03602532.2013.765445 via openalex
doi:10.1023/b:pham.0000016235.32639.23 via openalex
doi:10.1021/mp100377m via openalex
doi:10.1002/jps.10005 via openalex
doi:10.1016/j.ajps.2015.10.049 via openalex
doi:10.1016/j.ijpharm.2004.01.014 via openalex
W1709109739 via openalex
doi:10.1152/ajpregu.00262.2010 via openalex
doi:10.1124/dmd.109.030270 via openalex
doi:10.1208/s12248-009-9099-y via openalex
doi:10.1371/journal.pone.0068237 via openalex
doi:10.1023/a:1016062224568 via openalex

Cited by (1)

Danazol 2022

Source provenance

openalex: last seen: 2026-05-11T06:40:38.933960+00:00

License: CC0 · commercial use OK

[1] A dynamic in vitro lipolysis model via openalex

[2] Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats via openalex

[3] Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug via openalex

[4] Evaluation of a Nanoemulsion Formulation Strategy for Oral Bioavailability Enhancement of Danazol in Rats and Dogs via openalex

[5] Formulation and Performance of Danazol Nano-crystalline Suspensions and Spray Dried Powders via openalex

[6] Formulation of a Danazol Cocrystal with Controlled Supersaturation Plays an Essential Role in Improving Bioavailability via openalex

[7] <i>In Vivo</i> Precipitation of Poorly Soluble Drugs from Lipid-Based Drug Delivery Systems via openalex

[8] Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis via openalex

[9] Non-linear Increases in Danazol Exposure with Dose in Older vs. Younger Beagle Dogs: The Potential Role of Differences in Bile Salt Concentration, Thermodynamic Activity, and Formulation Digestion via openalex

[10] Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex

[11] Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules via openalex

[12] Solubilization and Wetting Effects of Bile Salts on the Dissolution of Steroids via openalex

[13] Surface treatment of the hydrophobic drug danazol to improve drug dissolution via openalex

[14] Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation via openalex

[15] W6635782166 via openalex

[16] W6676438963 via openalex

[17] W6682034404 via openalex

[18] W6685495014 via openalex

[19] W6687251196 via openalex

[20] doi:10.1371/annotation/10ae05dc-90cb-46f1-aa2b-e63eb4a132e2 via openalex

[21] doi:10.1002/jps.20212 via openalex

[22] doi:10.1023/b:modi.0000006562.93049.36 via openalex

[23] doi:10.2133/dmpk.24.53 via openalex

[24] doi:10.1016/s0928-0987(02)00251-8 via openalex

[25] doi:10.1007/978-1-4419-1087-5_10 via openalex

[26] doi:10.1016/j.addr.2016.04.018 via openalex

[27] doi:10.1016/j.jcis.2006.10.008 via openalex

[28] doi:10.1016/j.ejps.2013.02.006 via openalex

[29] doi:10.1007/s11095-008-9637-9 via openalex

[30] doi:10.1016/j.ijpharm.2008.10.001 via openalex

[31] doi:10.1007/s11095-016-1871-y via openalex

[32] doi:10.1002/bdd.2072 via openalex

[33] doi:10.1016/s0090-9556(24)15037-4 via openalex

[34] doi:10.1002/9783906390468 via openalex

[35] doi:10.1517/17425250802691074 via openalex

[36] doi:10.1021/js960075u via openalex

[37] doi:10.1016/j.ijpharm.2017.10.058 via openalex

[38] doi:10.1002/9783906390468.ch16 via openalex

[39] doi:10.1002/jps.22154 via openalex

[40] doi:10.5402/2012/195727 via openalex

[41] doi:10.1016/j.molliq.2016.02.081 via openalex

[42] doi:10.3109/03602532.2013.765445 via openalex

[43] doi:10.1023/b:pham.0000016235.32639.23 via openalex

[44] doi:10.1021/mp100377m via openalex

[45] doi:10.1002/jps.10005 via openalex

[46] doi:10.1016/j.ajps.2015.10.049 via openalex

[47] doi:10.1016/j.ijpharm.2004.01.014 via openalex

[48] W1709109739 via openalex

[49] doi:10.1152/ajpregu.00262.2010 via openalex

[50] doi:10.1124/dmd.109.030270 via openalex

[51] doi:10.1208/s12248-009-9099-y via openalex

[52] doi:10.1371/journal.pone.0068237 via openalex

[53] doi:10.1023/a:1016062224568 via openalex